As reported in Twin Cities Business on November 23rd, a team of researchers has patented a drug treatment that stimulates the production of progranulin (PGRN), a protein necessary in maintaining the health of the brain’s frontal and temporal lobes. Deficiencies of PGRN have been linked to both FTD and ALS. The researchers — led by the Mayo Clinic’s Rosa Rademakers, who received the Potamkin Prize earlier this year — also patented a benign virus designed to deliver the drug to the brain.